With nearly 30% shaved off the top of Idenix (IDIX -29%) today on the back of the FDA's partial...


With nearly 30% shaved off the top of Idenix (IDIX -29%) today on the back of the FDA's partial clinical hold placed on Phase 2 trials of its Hep c drug, Stifel Nicolaus steps in with a valuation upgrade. The firm raises the shares to Hold from Sell, noting that the hold is just temporary and likely to be resolved.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs